Our research projects

Finding which regulatory regions of the genome are causing leukaemia by acting on the wrong gene

Developing better models of rhabdomyosarcoma to test available treatments.

Our proposal will deliver novel, less toxic targeted therapies with the potential to advance current treatment regimens for B-ALL. This will improve current outcomes, reduce side-effects in B-ALL patients and ultimately lead to a better quality of life for patients and their families.

Ewing sarcoma is the second most common bone tumour in young people. The primary goal of this project is to fast-track a targeted drug combination for evaluation in clinical trials, with the aim of improving outcomes and minimising treatment associated morbidities for Ewing sarcoma patients.

Glo-BNHL trial is an international trial that will recruit children across the globe with relapse BNHL and assign them to the trial to receive a novel therapy. We are requesting funds to conduct biological studies alongside the trial to improve our understanding of this cancer.

Investigating a new method to improve the success of bone marrow transplants, using a different type of blood cells.

Immunotherapy could be a potential treatment for ependymoma. To make immunotherapy effective we need to know more about how ependymoma works.

Osteosarcoma bone cancer affects teenagers, around half of whom die within 5-years of diagnosis. We think we can solve these problems by modifying immune cells called “gamma-delta T-cells”.

Craniopharyngioma, a brain tumour affecting children, is difficult to treat. Work within the laboratories of the investigators has identified potential drugs that could turn off tumour growth. These drugs will be tested in patients whose tumours have regrown in a clinical trial.